OTIC - Otonomy, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

2.60

+0.01 (+0.39%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	2.59
Open	2.56
Bid	2.50 x 900
Ask	2.70 x 1400
Day's Range	2.56 - 2.66
52 Week Range	2.21 - 6.45
Volume	14,767
Avg. Volume	113,526

Market Cap	79.638M
Beta (3Y Monthly)	3.41
PE Ratio (TTM)	N/A
EPS (TTM)	-2.13
Earnings Date	Nov 6, 2018 - Nov 12, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	10.00

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire2 days ago
Report: Exploring Fundamental Drivers Behind St. Joe, Emerge Energy Services LP, Resources Connection, FormFactor, Global Brass and Copper, and Otonomy — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
GlobeNewswire18 days ago
Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
John Phillips, FRCS (ORL-HNS), Consultant Otolaryngologist at Norfolk & Norwich University Hospitals in the United Kingdom, will present the AVERTS-2 clinical trial results on Tuesday, October 9 at 1:27 p.m. EDT. The AVERTS-2 trial achieved its primary endpoint, count of definitive vertigo days (DVD) by Poisson Regression analysis in Month 3 (p value = 0.029), based on analysis of all 174 patients enrolled in the trial. "I am pleased to present the results from the AVERTS-2 trial, which is the first large-scale, randomized, placebo-controlled clinical trial to demonstrate a statistically significant improvement of vertigo in Ménière’s disease patients," said Mr. Phillips.
GlobeNewswire24 days ago
Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
SAN DIEGO, Sept. 25, 2018-- Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David A. Weber, Ph.D., president and chief ...
PR Newswirelast month
Oculis Elects Anthony Rosenberg and David A. Weber - Veterans of the Global Pharmaceutical and Eye-care Industries - to its Board of Directors
Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announces the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, Ph.D. as Non-Executive Director. "This is an exciting period for Oculis, as we look to advance and expand the clinical development of our lead candidate OC-118, a potential transformative topical treatment for Diabetic Macular Edema (DME).
Simply Wall St.last month
Who Owns Otonomy Inc (NASDAQ:OTIC)?
Every investor in Otonomy Inc (NASDAQ:OTIC) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decreaseRead More...
GlobeNewswire2 months ago
Research Report Identifies Blue Apron, Otonomy, InnerWorkings, Rent-A-Center, NOW, and Flotek Industries with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blue ...
Zacks2 months ago
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
Zacks2 months ago
Otonomy (OTIC) Reports Q2 Loss, Misses Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of -15.79% and -59.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Associated Press2 months ago
Otonomy: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of 44 cents per share. The biotechnology company posted revenue of $123,000 in the period. In the final minutes of trading on Wednesday, the company's shares ...
GlobeNewswire2 months ago
Otonomy Reports Second Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 08, 2018-- Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial results for the quarter ended June 30, ...
ACCESSWIRE2 months ago
Otonomy, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...
GlobeNewswire2 months ago
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the signing of a co-promotion agreement with Mission Pharmacal Company (“Mission”), a well-established privately held pharmaceutical company, that provides Mission with an exclusive right to promote OTIPRIO (ciprofloxacin otic suspension) for acute otitis externa (AOE) in pediatrician and primary care physician offices as well as urgent care clinics in the United States. Otonomy retains all commercial rights for other customer segments for AOE and use of OTIPRIO in all other indications including ongoing sales for use during pediatric ear tube surgery.
GlobeNewswire3 months ago
Otonomy to Report Second Quarter 2018 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 01, 2018-- Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results for the second ...
GlobeNewswire3 months ago
Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation of the additional Phase 3 trial required to support a submission for U.S. registration of OTIVIDEX in Ménière’s disease. “We are excited to initiate this trial for OTIVIDEX, which we believe is the remaining clinical requirement to bring a new treatment option to Ménière’s disease patients experiencing debilitating vertigo episodes,” said David A. Weber, Ph.D., president and CEO of Otonomy. The design and conduct of this pivotal trial is based on the successful AVERTS-2 Phase 3 trial.
ACCESSWIRE5 months ago
Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desk’s Radar
Stock Research Monitor: MBRX, OGEN, and OTIC LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration . On Friday, May 25, 2018, ...
Associated Press5 months ago
Otonomy: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 37 cents. The biotechnology company posted revenue of $301,000 in the period. In the final minutes of trading on Wednesday, the company's ...
Zacks6 months ago
Otonomy (OTIC) Sees Hammer Chart Pattern: Time to Buy?
Otonomy, Inc. (OTIC) has been struggling lately, but the selling pressure may be coming to an end soon
Benzinga7 months ago
Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing
JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech ...
Associated Press7 months ago
Otonomy reports 4Q loss
On a per-share basis, the San Diego-based company said it had a loss of 62 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
ACCESSWIRE7 months ago
Otonomy, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern Time. To listen ...